Wellmark coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

What you need to qualify

Age 18 and older
BMI of 30 or higher
BMI of 27 or higher with a weight-related condition (HTN, dyslipidemia, and CVD)
6 months of a documented diet and exercise program
Not being used to treat type 1 diabetes

Qualification pathways

You can qualify through any one of these.

Weight Loss - Continuation/Already on therapy

All of:

Patient is 18 years of age or older
Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose
Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Weight Loss - New to therapy with BMI >= 30

All of:

Patient is 18 years of age or older
Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Patient has a baseline BMI >= 30 kg/m2
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Weight Loss - New to therapy with BMI >= 27 and comorbidity

All of:

Patient is 18 years of age or older
Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
Patient has a baseline BMI >= 27 kg/m2
Patient has at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, or cardiovascular disease)
Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Documentation to bring

Chart notes or medical record documentation of Body Mass Index (BMI)
Chart notes or medical record documentation of weight-related comorbid condition, if applicable
Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

All strengths — 4 pens

Approval and renewal

Initial approval: 6 months
Renewal: every 12 months
To renew, the plan looks for at least 5% weight loss from the starting weight, Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1/GIP-GLP-1 approved for T2DM)
Combination use with another targeted weight loss agent
Plans without specific benefit language allowing weight loss drug coverage

Policy note: The Zepbound weight_loss and osa indications are covered under a single section IX. The BMI >= 27 with comorbidity pathway for weight loss lists cardiovascular disease as an accepted comorbidity (in addition to hypertension and dyslipidemia), which differs slightly from Wegovy's weight_loss pathway. Members receiving medication via samples or manufacturer patient assistance programs must meet initial approval criteria.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs-for-weight-loss-management.pdf